MOBIDIAG
10.2.2020 08:02:12 CET | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.
The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.
The new Novodiag® test will operate using a rapid ‘sample-in, result-out’ system, allowing the rapid detection of both novel coronavirus and influenzas in around 30 minutes. In addition, the fully automated system protects laboratory staff and healthcare providers from possible contamination. The user-friendly nature of the system will mean that the Novodiag® platform can be delivered to and will be targeted for use in high risk and hard to reach areas without the need for highly trained personnel.
Tuomas Tenkanen, CEO of Mobidiag, said, “It is vital that molecular diagnostics solutions be utilized to fight back against novel coronavirus which has emerged as a significant threat to health across the world. Our new Novodiag® assay will uniquely offer rapid and fully automated molecular profiling to simultaneously detect novel coronavirus and common influenza strains and guide clinicians more quickly towards moving patients to efficient isolation measures and make better-informed treatment decisions, in situations where time is critical.”
“Our partner Autobio’s understanding of the developing situation in China, combined with our in-house expertise and flexibility of the Novodiag® platform, means we are well positioned to develop an effective diagnostic solution for such a global health emergency. Regulators around the world have recognized the need to expedite responses to the diagnosis and treatment of novel coronavirus and we intend to bring our test to market as rapidly as possible.”
Fu Guangyu, Director of Autobio and General Manager of Automobi, said, “To control the spread of 2019-nCov as soon as possible, a rapid, safe, and accurate etiological diagnosis technique is of paramount need. We are delighted that Mobidiag will use its expertise and know-how to develop an assay that can be used on the Novodiag® platform at this critical time. Autobio and Automobi will work closely with Mobidiag by sharing relevant technology, experience, resources and information in order to ensure we make a meaningful impact in the fight against the spread of 2019-nCov.”
The development of this new assay highlights the broad flexibility and applicability of the Novodiag® platform which combines real-time PCR and microarray technologies to allow for single to high-plex (100+) diagnostics, enabling future applications in areas such as infectious diseases, sepsis and oncology. It conducts comprehensive screening of multiple or single pathogens within approximately one hour, helping to deliver early treatments to patients and avoid the spread of infection.
About Mobidiag Ltd.
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adaptability for large scale manufacturing, Mobidiag’s Amplidiag®
and Novodiag®
platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s initial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
About Autobio
Autobio Diagnostics Co., Ltd was established in 1998 and has become one of the largest and fastest growing clinical diagnostics companies in China. Autobio specialises in research & development, production, marketing and service of clinical diagnostic products, especially immunoassay, microbiology and biochemical products. Autobio provides comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016.
Autobio has more than 3700 staff and is headquartered in Zhengzhou, China. To learn more, visit www.autobio.com.cn
About AutoMobi
Automobi Molecular Diagnostic Co., Ltd., was jointly established by Autobio and Mobidiag in China in May 2019. It is mainly engaged in the development, sales and after-sales services of molecular diagnostic products. Automobi commercialises a series of molecular diagnostic products in the Greater China territory based on the Novodiag®
technology platform, and comprehensively screens multiple pathogens or single pathogens within one hour, which can meet the needs of all large and medium-sized laboratories through to grass-roots on-site testing.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200209005009/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacífico Mexinol Celebrates the Symbolic Groundbreaking in Topolobampo, Positioning Mexico in the New Low-Carbon Chemical Industry24.4.2026 02:29:00 CEST | Press release
The initiative brings together governments, diplomats, and global investors around a Net Zero industrial model. The project establishes Topolobampo, Sinaloa as a key hub for industrial development in North America. The Pacifico Mexinol project (“Mexinol”) celebrated the beginning of its pre-construction phase by symbolically laying a first stone, marking the start of one of the most significant global industrial investments in blue and ultra-low carbon methanol. The event brought together diplomats, authorities, and national and international business leaders, reflecting the project’s strategic importance for Mexico and its integration into the emerging low-carbon economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423775301/en/ Adolfo Murietta, Project Shareholder; Rommel Gallo, CEO Transition Industries; Ron Johnson, United States Ambassador to Mexico; Drew Hoster, Counsel General of the United States in Hermosillo,
The New World ID: Proof of Human for the AI Era Scales Across the Digital Platforms People and Businesses Use Every Day24.4.2026 02:20:00 CEST | Press release
Docusign, Okta, Tinder, Vercel, and Zoom bring World ID proof of human to businesses, AI agents, and consumers Last week, World announced the next generation of World ID, its proof of human protocol, designed to increase trust on the internet. The announcement was made during “Lift Off,” a live event in San Francisco. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417530721/en/ Docusign, Okta, Tinder, Vercel, and Zoom bring World ID proof of human to businesses, AI agents, and consumers As AI makes it easier than ever to generate convincing content, identities, and interactions, trust online has decreased. World ID addresses this challenge by enabling individuals to privately prove they are a real, unique human, without revealing their identity across apps, platforms, and services. “If anything online can be faked, you no longer know who or what to trust,” said Tiago Sada, Chief Product Officer at Tools for Humanity, a co
Cognite Positioned as a Front Runner in LNS Research Solution Selection Matrix for Industrial AI Platforms23.4.2026 20:00:00 CEST | Press release
Cognite, the global leader in Industrial AI, has been named a Front Runner in the LNS Research Solution Selection Matrix for Industrial AI Platforms (SSM). The LNS Research SSM evaluates vendors using a rigorous methodology that leverages its “3P” framework—Product, Potential, and Presence—to assess both current capabilities and future readiness. Within the report, Cognite is recognized in three key areas: depth in user-centric industrial AI applications, its knowledge graph-based data model, and its strong partner ecosystem. Together, all three give Cognite the ability to unify and contextualize complex industrial data, enabling organizations to operationalize AI at scale. “Cognite brings a sophisticated data model built for industrial complexities, along with advanced analytics and AI-driven insights, which is crucial for industrial organizations to achieve meaningful productivity gains and enterprise-wide ROI,” said Vivek Murugesan, Research Analyst at LNS Research. “These capabilit
Venture Global Announces Closing of $750,000,000 Senior Secured Notes by Venture Global Calcasieu Pass, LLC23.4.2026 19:47:00 CEST | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Calcasieu Pass, LLC (“VGCP”) has closed an offering of $750,000,000 aggregate principal amount of 6.000% senior secured notes due 2036 (the “Notes”). The Notes will mature on May 1, 2036. VGCP used the net proceeds from the offering, together with cash on hand and proceeds received from certain hedge terminations, for the prepayment, in full, of VGCP’s outstanding term loans, and to pay fees and expenses in connection with the offering. The Notes are guaranteed by TransCameron Pipeline, LLC (VGCP’s affiliate). The Notes are secured on a pari passu basis by a first-priority security interest in the assets that secure VGCP’s existing senior secured first lien credit facilities and VGCP’s existing senior secured notes. The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes
Does Muscle Composition Identify High-Risk Individuals in Chronic Kidney Disease? New AMRA Medical Study Says Yes, Reveals Strong Link to Mortality23.4.2026 17:10:00 CEST | Press release
AMRA Medical researchers recently set out to answer the question: what is the relationship between adverse muscle composition (AMC) and mortality in kidney disease? Recent findings demonstrate that AMC, characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD). The findings, published in Clinical Journal of the American Society of Nephrology, were based on data from the UK Biobank imaging study and further reinforce the clinical relevance of MRI-derived muscle biomarkers in identifying high-risk populations across chronic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423198497/en/ AMRA's MRI-based muscle biomarkers in clinical trials Researchers from AMRA, alongside our collaborators at Linköping University (LiU), analyzed 894 participants with CKD using AMRA’s MRI-based body composi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom